Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
about
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02Clinical Development of the E75 Vaccine in Breast CancerFinal report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patientsThe HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade.Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials.AE37: a novel T-cell-eliciting vaccine for breast cancer.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Therapeutic cancer vaccines: a long and winding road to success.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Adjuvant HER2/neu peptide cancer vaccines in breast cancer.Immunotherapy for breast cancer: past, present, and future.Peptide-Based Cancer Vaccine Strategies and Clinical Results.The development and use of the E75 (HER2 369-377) peptide vaccine.A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.Rethinking cancer vaccines to avoid T-cell traps.Breast Cancer Immunotherapy.Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.Immunotherapy of breast cancer
P2860
Q24611404-ECA49399-8AF4-478F-BADE-3B3F09380772Q26745440-054D03FF-5DAE-4A4D-AF89-5708E442D8E9Q34083121-EFC9B99D-6020-43E6-9F9B-32DF56EB6BF3Q35181440-942BB2B2-F54C-4B74-9DBE-8B44D88C4A3FQ36653524-681D97E2-542A-4F69-AB8D-5FDB11FA525CQ37662391-61F23205-DC4A-4FEC-96FD-75DC08E39D63Q37892580-5DA1C8BB-DF33-4019-B9FC-3E3E22DAF9E1Q37927091-226C577A-D0C5-4D91-9E1E-8493423006A1Q38076053-197FDECE-5F9A-42B5-9E45-8664EE82554AQ38162261-A64F6C28-E162-4625-BB55-AB4A69B25325Q38215394-65D827CB-69BD-4F5E-B370-BDB5FCCF8E30Q38633206-90AB0FE6-B318-4ADF-8E82-ECB581099E5DQ38787696-EE197472-5261-4F3C-B2DB-CC41569290FBQ38807849-CFDAB18D-370D-4915-97D6-E8796DCA8B18Q38885965-D3852C68-A28B-42A8-8E99-A02045051BE5Q50260488-60F11252-9A30-46A7-B699-8D4A0CCEC918Q50856300-1B14CDC5-8E7C-43A6-8C94-0743010813CCQ51108833-BCC2343F-89F3-4223-B162-3EA097C56803Q52638390-22BFC0D5-2FFB-4B84-83A0-097C4E1118BBQ57134389-BC085498-714C-470A-95D2-B6B4B4DDA61D
P2860
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@ast
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@en
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@nl
type
label
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@ast
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@en
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@nl
prefLabel
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@ast
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@en
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@nl
P2093
P2860
P356
P1433
P1476
Use of booster inoculations to ...... als Group Study I-01 and I-02.
@en
P2093
Alexander Stojadinovic
Elizabeth A Mittendorf
George E Peoples
Guy T Clifton
Jarrod P Holmes
Jeremy D Gates
Linda C Benavides
Ritesh Patil
Sathibalan Ponniah
P2860
P304
P356
10.1002/CNCR.25586
P407
P577
2010-09-15T00:00:00Z